Volume 18 - Issue 8 - August 2005
Continuing Education »
The bunion deformity is one of the most common deformities that podiatric foot and ankle surgeons treat. As with other conditions, the conservative and surgical measures vary based on the patient’s expectations and the surgeon’s experience. Although there are limited conservative options available such as shoe modifications and prescription orthoses, most podiatric physicians would agree that surgical correction is often necessary for a symptomatic bunion deformity.
While there are several considerations in choosing the appropriate surgical procedure,
The performance review can be a difficult proposition as there is a certain amount of dread and anticipation for both the employer and the employee. One must address the tricky issue of pay or salary. Performing a thorough performance review is also important from a legal perspective. For example, a fired employee may claim he or she was never told about a particular area of deficiency.
There is a desire to cover all the relevant areas and issues in the performance review but some people have trouble being tactful and honest at the same time. A common mi
Many of my colleagues have voiced concerns regarding the use of nutriceuticals in their practices. The expressed concerns range from “These things are unproven” and “There is no FDA scrutiny over these products” to “They don’t work all the time” and “There are no scientific, double-blind, placebo-controlled studies on their safety or effectiveness.”
I had many of the same doubts before I incorporated nutriceuticals into my practice over 12 years ago. Since my training in podiatry school was allopathic in nature, it was difficult for me t
New technologies abound and there is certainly no shortage of new innovations. There are new medications for diabetic neuropathic pain and antibiotic-resistant infections. There are innovative matrices that may enhance the healing environment for wounds. There are leading advances in the limb salvage arena as well as impressive modalities for facilitating bone healing. With that said, let us take a closer look at several new and emerging innovations that may prove beneficial to podiatrists and their patients.
1. Tigecycline (Tygacil™, Wye
Editor's Perspective »
What has always struck me about the podiatry profession is the diverse array of niches within the field. Podiatrists may specialize in the sports medicine arena or excel in ensuring appropriate wound care for high-risk patients with diabetes. Podiatric doctors may be known for their stellar surgical expertise while other DPMs have a strong knowledge of podiatric dermatology.
Addressing the diversity of the podiatric experience is a challenge that we look forward to with each issue. Nowhere is this diversity more apparent than in this month's edition, one
Diabetes Watch »
As we evolve in our treatment of foot and ankle conditions, it seems like each treatment meets with some reservation from the medical community. As podiatric physicians, our mindset is scientific in nature and we need hard facts and evidence-based results to show each treatment option is beneficial. I am with the mainstream in that thinking but I also try to rationalize a treatment option and see why it may or may not benefit a patient.
To that extent, there has been a great deal of interest in treatment options for diabetic neuropathy. A. Lee Dellon, MD
- « Previous
- | Page 1 of 3 |
- Next »